Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech A/S, a company focused on developing advanced software for new immune therapies and vaccines, has a share capital of DKK 54,110,546 with shares that are non-negotiable instruments. The board of directors is authorized to issue warrants and increase share capital up to DKK 9,461,540 until April 15, 2029, to incentivize key company personnel, without preemptive rights for existing shareholders. Shares from warrants are subject to the same transfer restrictions as current shares and give rights to dividends and other company benefits.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
